These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22526313)

  • 1. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
    Tsuji BT; Brown T; Parasrampuria R; Brazeau DA; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Hanna D; Bulitta JB
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3712-9. PubMed ID: 22526313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
    Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
    J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
    Louie A; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.
    Pichereau S; Pantrangi M; Couet W; Badiou C; Lina G; Shukla SK; Rose WE
    Antimicrob Agents Chemother; 2012 Jan; 56(1):140-7. PubMed ID: 22064533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.
    Keel RA; Tessier PR; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.
    Candel FJ; Morales G; Picazo JJ
    Rev Esp Quimioter; 2011 Sep; 24(3):127-30. PubMed ID: 21947094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM; Li J; Rayner CR; Nation RL
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
    Baldoni D; Haschke M; Rajacic Z; Zimmerli W; Trampuz A
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1142-8. PubMed ID: 19075065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
    LaPlante KL; Leonard SN; Andes DR; Craig WA; Rybak MJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2156-62. PubMed ID: 18411321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.